These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 18381454)
1. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer. Jorritsma A; Bins AD; Schumacher TN; Haanen JB Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454 [TBL] [Abstract][Full Text] [Related]
2. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy. Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722 [TBL] [Abstract][Full Text] [Related]
3. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine]. Ma J; Wang YL; Hu HM; Fox BA; Si LS Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
5. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401 [TBL] [Abstract][Full Text] [Related]
6. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463 [TBL] [Abstract][Full Text] [Related]
7. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
8. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758 [TBL] [Abstract][Full Text] [Related]
10. Decreased tumor surveillance after adoptive T-cell therapy. Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217 [TBL] [Abstract][Full Text] [Related]
11. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Ly LV; Sluijter M; Versluis M; Luyten GP; van Stipdonk MJ; van der Burg SH; Melief CJ; Jager MJ; van Hall T Cancer Res; 2010 Nov; 70(21):8339-46. PubMed ID: 20940397 [TBL] [Abstract][Full Text] [Related]
12. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626 [TBL] [Abstract][Full Text] [Related]
13. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells. Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262 [TBL] [Abstract][Full Text] [Related]
14. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy. Mueller K; Schweier O; Pircher H Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743 [TBL] [Abstract][Full Text] [Related]
16. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082 [TBL] [Abstract][Full Text] [Related]
17. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Kudo-Saito C; Schlom J; Hodge JW Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693 [TBL] [Abstract][Full Text] [Related]
18. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937 [TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372 [TBL] [Abstract][Full Text] [Related]
20. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Teshima T; Liu C; Lowler KP; Dranoff G; Ferrara JL Cancer Res; 2002 Feb; 62(3):796-800. PubMed ID: 11830535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]